Companies with technology platforms that address only a tiny part of the drug discovery process risk becoming optional or redundant accessories. The concept of business models has been a favorite ...

we believe the industry is now undergoing a fundamental change that will necessitate the creation of a radically new business model. While previously biotechnology companies attempted to emulate ...